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Summary
Background: Acute hyperglycemia is associated with increased mortality rates in
patients with acute coronary syndrome.
Objective: This study aimed to evaluate the relationship between the glucose level
and clinical variables during primary intervention in patients with ST-elevation acute
myocardial infarction (STEMI).
Methods and results: Of consecutive 94 patients with STEMI treated by primary stent
implantation, acute hyperglycemia (plasma glucose level on admission > 198mg/dl)
was recognized in 29 patients. There were no signiﬁcant differences in baseline char-
acteristics, except for the presence of diabetes and HbA1c level, between patients
with and without acute hyperglycemia. In patients with acute hyperglycemia, cor-
rected TIMI frame counts were signiﬁcantly higher compared with those in patients
without acute hyperglycemia (46.3± 30.3 vs. 34.0± 17.9, p = 0.02). And corrected
TIMI frame count was independently associated with plasma glucose level (p = 0.006).
Maximum level of creatine kinase (CK) and CK-MB were signiﬁcantly higher in
patients with acute hyperglycemia (CK, 4840.0± 4690.3 vs. 2410.7± 2302.9 IU,
p = 0.001; CK-MB, 315.3± 257.7 vs. 195.9± 191.1, p = 0.01).
Conclusion: The presence of acute hyperglycemia was associated with the impair-
ment of epicardial coronary ﬂow after primary stent implantation. This mechanism
might be responsible for th
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ntroduction
yperglycemia on admission in patients with acute
oronary syndrome is common, and it is reported
o be independently associated with poor prognosis
ven in the primary intervention era [1—9]. Acute
yperglycemia is associated with large infarct
ize, left ventricular dysfunction, and short-term
ortality after acute myocardial infarction (AMI)
egardless of diabetic status [2—8]. The underly-
ng mechanisms of this adverse prognostic impact
f acute hyperglycemia, however, have not been
ully elucidated. It has been reported that hyper-
lycemia impairs microvascular function which may
ause the no-reﬂow phenomenon [10]. The no-
eﬂow phenomenon, which is characterized by
mpaired myocardial perfusion despite reopening
f the epicardial coronary artery, can occur during
oronary intervention in patients with AMI and is
redictive of poor prognosis. The aim of this study
as to test the hypothesis that acute hyperglycemia
ight cause the impairment of coronary ﬂow and
yocardial perfusion after primary stent implanta-
ion in patients with ST-elevation acute myocardial
nfarction (STEMI).
ethods
etween August 2005 and July 2006, 94 consecutive
atients with STEMI who were treated with pri-
ary stent implantation within 24 h of onset were
nrolled. We excluded patients with bypass graft
esions, left main trunk lesion, subacute thrombo-
is, or stent implantation using distal protection
evice. Written informed consent was obtained
rom all patients. All patients were premedicated
ith aspirin (162mg orally), and unfractionated
eparin (10,000 IU) was administered intravenously
uring the procedure. A conventional guidewire was
dvanced across the target lesion, and thrombec-
omy and/or pre-dilation with a small balloon
2.0mm) was performed to achieve the TIMI 3
ow. The stent was implanted based on intravas-
ular ultrasound measurements to obtain < 25%
ngiographic residual stenosis. Immediately after
ntervention, TIMI ﬂow grade [11], corrected TIMI
rame counts [12] and myocardial blush grade [13]
ere evaluated. ST-segment resolution was deﬁned
s > 50% resolution of ST-segment elevation as pre-
iously described [14]. Acute hyperglycemia was
eﬁned as plasma glucose of > 11 mmol (198mg/dL)
n admission. Maximum creatine kinase (CK) level
nd CK myocardial fraction (CK-MB) were deter-
ined from blood samples obtained every 4 h
d
s
s
w
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ollowing revascularization. Statistical analysis was
erformed with StatView (SAS Institute, Cary, NC,
SA). Continuous variables were compared by the
npaired Student’s t-test. Categorical variables
ere compared by the chi-square analysis. Non-
arametric Spearman’s correlation method was
sed for correlation analysis. Multivariable linear
egression analyses examined the correlation of
orrected TIMI frame counts and baselines variables
hat were associated with cTIMI frame counts at
he p < 0.10 level in the univariate analyses. For all
nalyses, a p-value < 0.05 was deﬁned as statisti-
ally signiﬁcant.
esults
f 94 patients, acute hyperglycemia was observed
n 29 (31%). There were no signiﬁcant differ-
nces in baseline characteristics, except for the
resence of diabetes, between patients with and
ithout acute hyperglycemia (Table 1). Table 2
hows the comparison of clinical variables, ﬁnal
IMI ﬂow grade and myocardial blush grade were
imilar between the two groups, however the cor-
ected TIMI frame counts were signiﬁcantly higher
n patients with acute hyperglycemia (46.3± 30.3
s. 34.0± 17.9, p = 0.02). Maximum CK level and
K-MB level were signiﬁcantly higher in patients
ith acute hyperglycemia (CK, 4840.0± 4690.3 vs.
410.7± 2302.9 IU, p = 0.001; CK-MB, 315.3± 257.7
s. 195.9± 191.1, p = 0.01). In multivariate anal-
sis, the corrected TIMI frame counts were
ndependently affected by glucose level on admis-
ion and reference diameter of infarct-related
esion (Table 3).
iscussion
ur result showed that higher glucose levels on
dmission were associated with reduced epicardial
oronary ﬂow after primary stent implantation in
atients with STEMI, and acute hyperglycemia was
ssociated with increased infarct size.
In prior studies, the prevalence of hyper-
lycemia on admission ranged from 20% to 50% of
atients with acute coronary syndrome, although
he exact deﬁnition of hyperglycemia has not been
stablished [3—5]. Even after excluding preexisting
iabetic patients, hyperglycemia in acute coronary
yndrome remains a common ﬁnding [15,16]. In our
tudy, glucose level > 11.0mmol/L on admission
as observed in 31% of all subjects and 15% of
on-preexisting diabetic subjects. Clinical studies
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Table 1 Baseline characteristics of subjects with and without acute hyperglycemia.
Variable Acute hyperglycemia P-value
No (N = 65) Yes (N = 29)
Age (years) 67.0± 12.4 64.5± 9.8 0.34
Men 51 (79%) 22 (76%) 0.78
Hypertension 34 (52%) 14 (48%) 0.72
Hyperlipidemia 33 (51%) 12 (41%) 0.36
Diabetes 7 (11%) 18 (62%) 0.0001
HbA1c (%) 5.4± 1.0 7.5± 1.8 <0.0001
Glucose (mg/dl) 136± 26 283± 96 <0.0001
Current smoking 29 (45%) 19 (66%) 0.07
Past myocardial infarction 8 (12%) 4 (14%) 0.84
Pre-infarct angina 33 (51%) 11 (38%) 0.22
Time to reperfusion (h) 12.1± 26.0 10.3± 19.3 0.75
Killip classes > 2 11 (17%) 8 (28%) 0.11
Neutrophil (/l) 8396± 3190 7417± 3397 0.34
C-reactive protein (mg/dl) 0.58± 1.20 0.90± 2.99 0.49
Infarct-related artery 0.10
Left anterior descending 23 (35%) 13 (45%)
Left circumﬂex 15 (23%) 3 (10%)
Right 27 (42%) 13 (45%)
Triple vessel disease 6 (9%) 6 (21%) 0.11
Collateral circulation 6 (9%) 2 (8%) 0.67
Initial TIMI grade: 0 / 1 40 (62%) 21 (72%) 0.31
Quantitative angiography
Reference diameter (mm) 2.66± 0.59 2.76± 0.67 0.52
Minimum lumen diameter (mm) 0.40± 0.42 0.25± 0.39 0.11
Lesion length (mm) 14.7± 4.9 16.9± 9.0 0.13
65%)
h
i
h
a
aThrombectomy before stenting 42 (
Values are mean± SEM or number of patients (%).
have suggested that acute hyperglycemia is asso-
ciated with mortality and in-hospital complication
in patients with STEMI receiving thrombolytic
therapy [4] and primary coronary intervention
[7,8]. A meta-analysis of 15 articles also showed
that acute hyperglycemia with AMI was associated
with increased risk of in-hospital mortality in
patients with and without a history of diabetes [3].
These results lead to the question whether acute
t
l
i
w
Table 2 Comparison of clinical variables after interv
hyperglycemia.
Variable Acute hype
No (N = 65)
Final TIMI-3 58 (89)
Corrected TIMI frame count 34.0± 17
Myocardial blush grade: 2 or 3 44 (68)
ST resolution; >50% 42 (65)
Max. CK, IU 2410.7± 23
Max. CK-MB, IU 195.9± 19
Values are mean± SEM or number of patients (%). CK, creatine kina21 (72%) 0.26
yperglycemia directly inﬂuences clinical course or
s a simple marker of infarct size or severity. Acute
yperglycemia may represent stress response medi-
ted through the release of catecholamine and
drenal corticosteroids [17]. These responses of
he autonomic nervous system are associated with
arger infarct size, heart failure, and hemodynamic
nstability [18,19]. In our study, hyperglycemia
as associated with poorer epicardial coronary
ention between subjects with and without acute
rglycemia P-value
Yes (N = 29)
22 (76) 0.10
.9 46.3± 30.3 0.02
16 (55) 0.11
14 (48) 0.14
02.9 4840.0± 4690.3 0.001
1.1 315.3± 257.7 0.01
se; CK-MB, creatine kinase myocardial fraction.
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Table 3 Univariate and multivariate predictors of the cTIMI frame count.
Variable Univariate
coefﬁcients
P-value Multivariate coefﬁcients
(95% CI)
P-value
Age (years) −0.32 0.03 −0.19 (−0.59—0.21) 0.35
Gender (male) 0.003 0.98
Hypertension −0.24 0.13
Hyperlipidemia −0.002 0.98
Current smoking −0.014 0.93
Pre-infarct angina −0.07 0.67
Time to reperfusion (h) −0.06 0.70
Neutrophil (/l) −0.01 0.93
C-reactive protein (mg/dl) −0.07 0.56
Reference diameter (mm) 0.35 0.02 9.85 (2.41—17.3) 0.01
Lesion length (mm) −0.03 0.86
Thrombectomy before stenting 0.10 0.53
0
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Glucose level (mg/dl) 0.31
ow after stent implantation and the increased
nfarct size. The no-reﬂow phenomenon, which is
haracterized by impaired myocardial perfusion
espite reopening of the epicardial coronary artery,
ccurs during intervention in patients with AMI and
s predictive of poor prognosis [20,21]. A clinical
tudy using myocardial contrast echocardiography
as reported that hyperglycemia was associated
ith no-reﬂow phenomenon in AMI patients with
uccessful reperfusion by primary intervention
10]. Recently, Takahashi et al. have reported that
cute hyperglycemia attenuates the protective
ffects of pre-infarction angina on microvascular
unction in patients with AMI [22]. A study in
ealthy young adults has reported that acute
yperglycemia induced by oral glucose loading
uppresses coronary microcirculation [23]. Hyper-
lycemia and insulin resistance were reported to
nvolve pathological ST depression in exercise elec-
rocardiography [24]. Hyperglycemia causes the
romotion of oxidative stress [25], impairment of
ndothelial function [26], activation of coagulation
27,28], ampliﬁcation of inﬂammation [29,30],
romoting apoptosis by impairment of ischemic
reconditioning [31], and reduction of collateral
lood supply into ischemic zones [32]. Further-
ore, acute hyperglycemia increases intercellular
dhesion molecule-1 or P-selectin level, which
ould enhance leukocyte capillary plugging in the
oronary microcirculation [33]. These ﬁndings have
uggested that acute hyperglycemia might have
nduced microcirculation dysfunction, no-reﬂow
henomenon, during primary stent implantation in
atients with STEMI.
Regardless of cause, acute hyperglycemia may
e associated with unfavorable outcomes, thus
cute hyperglycemia has been offered as a target.13
.04 0.07 (0.02—0.13) 0.006
or treatment. In some randomized trials, however,
he beneﬁt of glucose control in patients with STEMI
as been inconsistent [34—37]. Most of these trials
ailed to achieve the target glucose level (normal
lucose level) and to start treatment early after
he onset of symptoms. Even in the DIGAMI trial
hich is the only trial to report a mortality beneﬁt,
he treatment of tight glucose control started 13 h
fter symptom onset [36]. Our study suggested that
cute hyperglycemia might have been associated
ith coronary ﬂow during reperfusion by primary
oronary intervention. Therefore, the initiation of
ight glucose control might be better before reper-
usion therapy.
Several limitations should be noted. This is a sin-
le center study with a small number of patients,
hus possibly posing a risk of patient selection bias.
e did not evaluate the coronary ﬂow and the
yocardial perfusion by other diagnostic modal-
ties including intracoronary ﬂow wire, contrast
chocardiography, and MRI.
In conclusion, acute hyperglycemia was associ-
ted with poor coronary ﬂow during primary stent
mplantation in patients with STEMI in this study.
urther studies addressing whether the treatment
f acute hyperglycemia improves coronary ﬂow and
linical outcomes will be necessary.
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